The program is run by the agency’s Office of Orphan Products Development. The guidance explains how manufacturers should define a patient population for the device, demonstrate the device’s efficacy for that group and how demonstrating efficacy varies whether the device treats or diagnoses a disease or condition.
Related Articles on the FDA:
Commentary: Free the FDA
FDA Approves Intuitive Surgical’s Single-Site Instrumentation for Gallbladder Surgery
FDA Finds Problems in Johnson & Johnson Contract Drug Factory
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
